Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $3.03 million.

“We have completed our first full quarter of commercial activities, adapting to the unprecedented challenges of the COVID-19 pandemic, and I am encouraged by CAPLYTA’s week over week prescription growth and increasing prescriber base,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “I am pleased with our team’s performance in the current environment, the positive physician response to CAPLYTA and the impact we are making in the lives of patients suffering from schizophrenia. We are also excited about advancements in our pipeline, including the upcoming announcement of results from our Phase 3 clinical trial evaluating lumateperone as an adjunctive treatment in bipolar depression (Study 402) and the continued progress in our other pipeline programs.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• Scilex (SCLX) Provides Preliminary Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024
• Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls